Share:

Top Back to top

EBMT Leaders Share Their Vision for the Future of Transplantation and Cellular Therapy

EBMT Organization

In a new video, six members of EBMT leadership reflect on the challenges, opportunities, and priorities that will shape the future of our Society and the wider transplant and cellular therapy community. The discussion brings together perspectives from across EBMT's leadership and explores key themes that underpin the EBMT Strategic Plan 2026-2030. 

Featured in the video are: 

  • Ibrahim Yakoub-Agha, EBMT President

  • Yann Mahé, EBMT Managing Director 

  • Antonio Risitano, Scientific Council Chair with the Research and Sciences Portfolio and Severe Aplastic Anaemia Working Party Chair 

  • Krzysztof Kałwak, Scientific Council Co-Chair with the Research and Sciences Portfolio and Paediatric Diseases Working Party Chair 

  • Jürgen Kuball, Scientific Council Representative with the Registry Portfolio and Cellular Therapy and Immunobiology Working Party Chair 

  • Raffaella Greco, EBMT Secretary 

Together, they share their vision for advancing transplantation and cellular therapies, generating evidence to improve patient care, strengthening education and professional development, and fostering collaboration across the global EBMT community. 

From Better Survival to Better Lives 

A recurring message throughout the interviews is that success in transplantation and cellular therapy extends beyond survival alone. As treatments become more sophisticated and patients live longer, increasing attention must be paid to long-term outcomes and quality of life. 

The leaders discuss the importance of ensuring that scientific and clinical advances ultimately translate into meaningful benefits for patients and their families, while helping healthcare professionals deliver the highest standards of care. 

The EBMT Registry: A Cornerstone of Evidence Generation 

The interviews highlight the central role of the EBMT Registry in advancing knowledge and improving outcomes across the field. 

For more than five decades, the Registry has provided a unique source of real-world data, supporting clinical research, benchmarking, outcome analysis, and evidence generation. Looking ahead, EBMT aims to further simplify data collection, strengthen international collaboration, and enhance the value of Registry data for centres, researchers, and patients alike. 

As novel therapies continue to emerge, robust data collection and analysis will remain essential to understanding long-term effectiveness, safety, and access to care. 

Embracing Innovation in Cellular Therapy 

The leadership discussion also explores the rapidly expanding landscape of cellular and gene therapies. 

From CAR-T cell therapies to future generations of advanced therapeutic approaches, innovation is transforming treatment possibilities for patients with haematological diseases. The interviewees emphasise the importance of combining innovation with high-quality evidence generation to ensure that new therapies can be integrated safely, effectively, and equitably into clinical practice. 

Supporting the Next Generation Through Education 

Education remains a fundamental pillar of the EBMT mission. 

The video showcases a range of initiatives designed to support professional development across the multidisciplinary transplant and cellular therapy workforce, including educational programmes, examinations, observerships, harmonisation activities, and career-development opportunities. 

By investing in education and training, EBMT aims to help healthcare professionals across all disciplines acquire the knowledge and skills required to meet the challenges of a rapidly evolving field. 

Building "One EBMT" 

Another key theme emerging from the interviews is the vision of "One EBMT". 

By strengthening collaboration across committees, working parties, professional groups, and member centres, EBMT aims to create a more connected and agile organisation that can better serve its members and respond to the needs of the transplant and cellular therapy community. 

Through greater integration, digital innovation, and closer engagement with stakeholders, the Society seeks to maximise its collective impact and continue driving progress worldwide. 

Delivering on the Strategic Plan 2026-2030 

The priorities discussed throughout the interviews reflect the ambitions set out in the EBMT Strategic Plan 2026-2030, which provides a roadmap for the Society's future development. 

The plan outlines EBMT's commitment to scientific excellence, innovation, education, data-driven decision-making, patient-centred care, and global collaboration. 

Readers can explore the full Strategic Plan here: 

Hear directly from EBMT's leadership as they share their perspectives on the future of transplantation and cellular therapy, the opportunities ahead, and the collective efforts required to improve outcomes for patients worldwide.